Pharmaceutical tariffs may not bring industry back to US, industry reps say
Implementing Section 232 tariffs on imported pharmaceuticals could discourage innovation and may not lead to the repatriation of the pharmaceutical supply chain to the US as intended, two pharmaceutical industry representatives...To view the full article, register now.
Already a subscriber? Click here to view full article